Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial.
- Published In:
- Diabetes care, 39(4), 596-602 (2016)
- Authors:
- Wahren, John, Foyt, Howard, Daniels, Mark, Arezzo, Joseph C
- Database ID:
- RPEP-03150
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03150APA
Wahren, John; Foyt, Howard; Daniels, Mark; Arezzo, Joseph C. (2016). Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial.. Diabetes care, 39(4), 596-602. https://doi.org/10.2337/dc15-2068
MLA
Wahren, John, et al. "Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial.." Diabetes care, 2016. https://doi.org/10.2337/dc15-2068
RethinkPeptides
RethinkPeptides Research Database. "Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 1..." RPEP-03150. Retrieved from https://rethinkpeptides.com/research/wahren-2016-longacting-cpeptide-and-neuropathy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.